JAMA Network
About The Study: Following landmark clinical trials and changes in guideline recommendations, self-reported primary prevention aspirin use decreased among older adults and adults with low atherosclerotic cardiovascular disease (ASCVD) risk for whom aspirin was not recommended, but also decreased among adults with higher ASCVD risk for whom aspirin may still be recommended. Despite these reductions, many patients with limited likelihood to benefit reported continuing to take aspirin.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
